These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 4097359)

  • 21. Depostat for benign prostatic hyperplasia?
    Drug Ther Bull; 1973 Sep; 11(19):75-6. PubMed ID: 4130364
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of prostatic hypertrophy with depostat].
    Nuri M; Hochberg K
    Munch Med Wochenschr; 1970 May; 112(22):1057-60. PubMed ID: 4192989
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of benign prostatic hypertrophy with medrogestone.
    Rangno RE; McLeod PJ; Ruedy J; Ogilvie RI
    Clin Pharmacol Ther; 1971; 12(4):658-65. PubMed ID: 4105445
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trial of gestronol hexanoate (SH582) in benign prostatic hypertrophy.
    Gengell JC; Miller IM; Roberts JB
    Proc R Soc Med; 1972 Feb; 65(2):130. PubMed ID: 4117437
    [No Abstract]   [Full Text] [Related]  

  • 25. [Gestonorone therapy of prostatic adenoma].
    Lopatkin N; Darenkow A; Sahmatow J; Tankó A; Ignaschin N; Warentsow G
    Acta Chir Acad Sci Hung; 1980; 21(4):271-8. PubMed ID: 6175122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone metabolism in benign prostatic hypertrophy. Suppression by diethylstilbestrol and gestonorone capronate.
    Orestano F; Klose K; Rubin A; Knapstein P; Altwein JE
    Invest Urol; 1974 Sep; 12(2):151-6. PubMed ID: 4137236
    [No Abstract]   [Full Text] [Related]  

  • 27. Gestronol hexanoate (SH582) and benign prostatic hypertrophy.
    Pitchford AG
    Proc R Soc Med; 1972 Feb; 65(2):128-9. PubMed ID: 4117436
    [No Abstract]   [Full Text] [Related]  

  • 28. [Comparative clinical study of betamethasone-17-valerate cream and fluocortolone-fluocortolone-21-capronate cream].
    Pfitzer G; Schröter R
    Hautarzt; 1971 Jul; 22(7):299-305. PubMed ID: 4398241
    [No Abstract]   [Full Text] [Related]  

  • 29. Conservative treatment of benign prostatic hyperplasia.
    Palanca E; Juco W
    Curr Med Res Opin; 1977; 4(7):513-20. PubMed ID: 66118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Medical therapy of benign prostatic hyperplasia: cyproterone acetate vs gestonorone caproate].
    Di Silverio F
    Minerva Urol Nefrol; 1986; 38(2):163-71. PubMed ID: 2428120
    [No Abstract]   [Full Text] [Related]  

  • 31. [On the treatment of prostatic adenoma with hydroxyprogesterone caronate].
    Ibba AL
    Osp Ital Chir; 1968; 19(4):427-42. PubMed ID: 4180617
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical experiences with phyto-therapy of benign prostatic hypertrophy].
    Bauer KM
    Med Welt; 1980 Aug; 31(34):1211-4. PubMed ID: 6159518
    [No Abstract]   [Full Text] [Related]  

  • 33. [Influence of gestonoron-capronate (GC) upon uptake and metabolism of H3-testosteron in benign prostatic hypertrophy (BPH): in vivo-experiments (author's transl)].
    Orestano F; Bandhauer K; Altwein JE
    Urologe A; 1974 Nov; 13(6):289-92. PubMed ID: 4141158
    [No Abstract]   [Full Text] [Related]  

  • 34. [Role of apha-blockaders in the treatment of prostatism].
    Penders L; Bouffioux C
    Acta Urol Belg; 1983; 51(4):518-31. PubMed ID: 6196958
    [No Abstract]   [Full Text] [Related]  

  • 35. [Nuclear content of deoxyribonucleic acid in the epithelium of hypertrophic prostate and prostatic carcinoma].
    Yamauchi A
    Nihon Hinyokika Gakkai Zasshi; 1970 Dec; 61(12):1170-83. PubMed ID: 4099311
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical effect of PPC for the palliative treatment of benign prostatic hypertrophy].
    Ishigami J; Kuroda K
    Hinyokika Kiyo; 1969 Jan; 15(1):68-75. PubMed ID: 4180035
    [No Abstract]   [Full Text] [Related]  

  • 37. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism].
    Iguchi H; Ikeuchi T; Kai Y; Yoshida H
    Hinyokika Kiyo; 1994 Mar; 40(3):215-9. PubMed ID: 7513937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Caproate of 17-alpha-hydroxy-19-nor-progesterone as an injectable contraceptive agent of lasting effect].
    Rodríguez-Restrepo R
    Rev Colomb Obstet Ginecol; 1969; 20(4):247-55. PubMed ID: 5356117
    [No Abstract]   [Full Text] [Related]  

  • 40. [Results of treating prostatic adenoma with Depostat].
    Darenkov AF; Zakhvatov IuM; Tanko A; Ignashin NS; Varentsov GI
    Urol Nefrol (Mosk); 1980; (5):34-7. PubMed ID: 6158780
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.